Syed Muhammad Muneeb Akhtar, Abraish Ali, Muhammad Sohaib Khan, Vareesha Khan, Areeba Fareed, Syed Zia Saleem, Munazza Mumtaz, Muhammad Nadeem Ahsan, Sadia Iqbal, Muhammad Sohaib Asghar
BACKGROUND: Vasomotor symptoms (VMS), such as hot flashes and night sweats, are highly prevalent and burdensome for women experiencing menopausal transition. Fezolinetant, a selective neurokinin 3 receptor (NK3R) antagonist, is a potential therapeutic option for mitigating VMS. OBJECTIVES: Our aim is to assess the efficacy and evaluate the safety profile of fezolinetant compared with placebo in post-menopausal women suffering from VMS, by pooling all the relevant data and reflecting the most current evidence...
April 2, 2024: International Journal of Gynaecology and Obstetrics